Biotechnology start-up Gain Therapeutics Inc. has begun trading on Nasdaq (New York) with the symbol “GANX” and an initial public offering of 3,636,364 shares at $11 each.
BTIG, LLC and Oppenheimer & Co. Inc. are serving as book-running managers for the offering and National Securities Corporation as co-manager.
Gain Therapeutics is developing new-generation pharmacological chaperones to treat rare diseases using proprietary SEE-Tx® technology (from Catalan firm Minoryx Therapeutics). Its pipeline covers five active programmes, including GM1 gangliosidosis, Gaucher disease, Parkinson, Mucopolysaccharidosis type 1 and Krabbe disease.
The company, founded in 2018, is based in Lugano (Switzerland) and has its R&D department at the Barcelona Science Park, led by Chief Scientific Officer Xavier Barril. The company CEO is Eric I. Richman.
Gain Therapeutics recently became a member of CataloniaBio&HealthTech. Listen to Xavier Barril:
Comments